The ROE as of October 2024 (TTM) for Kineta, Inc. (KA) is 934.78%

According to Kineta, Inc.’s latest financial reports and current stock price. The company's current ROE is 934.78%. This represents a change of -3910.94% compared to the average of -24.53% of the last 4 quarters.

Kineta, Inc. (KA) Historical ROE (quarterly & annually)

How has KA ROE performed in the past?

The mean historical ROE of Kineta, Inc. over the last ten years is -292.18%. The current 934.78% ROE has changed -419.93% with respect to the historical average. Over the past ten years (40 quarters), KA's ROE was at its highest in in the March 2023 quarter at 3.90%. The ROE was at its lowest in in the December 2022 quarter at -1061.69%.

Kineta, Inc. (KA) ROE by Quarter and Year

Discovering the peaks and valleys of Kineta, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kineta, Inc. (KA) Average ROE

How has KA ROE performed in the past?

The current ROE of Kineta, Inc. (KA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kineta, Inc. (KA) ROE vs. Peers

How is KA’s ROE compared to its peers?

Kineta, Inc.’s ROE is greater than Rezolute, Inc. (-70.73%), greater than Cyteir Therapeutics, Inc. (-23.13%), greater than XOMA Corporation (-19.34%), greater than Protagenic Therapeutics, Inc. (-238.37%), greater than Tempest Therapeutics, Inc. (-201.10%), greater than Candel Therapeutics, Inc. (-629.29%), less than MiNK Therapeutics, Inc. (99.78%), greater than Forte Biosciences, Inc. (-117.85%), greater than AlloVir, Inc. (-96.48%), greater than Dyadic International, Inc. (-145.95%), greater than DiaMedica Therapeutics Inc. (-38.56%), greater than Kintara Therapeutics, Inc. (-454.05%), greater than Silo Pharma, Inc. (-56.41%), greater than Protagenic Therapeutics, Inc. (-238.37%), greater than Lumos Pharma, Inc. (-157.99%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), greater than Molecular Partners AG (-33.08%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than AN2 Therapeutics, Inc. (-54.72%), greater than Pharvaris N.V. (-36.89%), greater than PepGen Inc. (-62.74%),

Build a custom stock screener for Kineta, Inc. (KA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kineta, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kineta, Inc. (KA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kineta, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.